Urinary concentrations and antibacterial activities of nitroxoline at 250 milligrams versus trimethoprim at 200 milligrams against uropathogens in healthy volunteers.
Because of the increasing bacterial resistance of uropathogens against standard antibiotics, such as trimethoprim (TMP), older antimicrobial drugs, such as nitroxoline (NTX), should be reevaluated. This randomized crossover study investigated the urinary concentrations of parent drugs and their metabolites and their antibacterial activities (urinary inhibitory titers [UITs] and urinary bactericidal titers [UBTs]) against uropathogens at three different urinary pH values within 24 h in six healthy volunteers after a single oral dose of NTX at 250 mg versus TMP at 200 mg. In three additional volunteers, urinary bactericidal kinetics (UBK) were studied after oral administration of NTX at 250 mg three times a day. The mean urinary concentrations of NTX and NTX sulfate in 24 h were 0.012 to 0.507 mg/liter and 0.28 to 27.83 mg/liter, respectively. The mean urinary concentrations of TMP were 18.79 to 41.59 mg/liter. The antibacterial activity of NTX was higher in acidic urine than in alkaline urine, and that of TMP was higher in alkaline urine than in acidic urine. The UITs and UBTs of NTX were generally lower than those of TMP except for a TMP-resistant Escherichia coli strain, for which NTX showed higher UITs/UBTs than did TMP. UBK showed mainly bacteriostatic activity of NTX in urine. NTX exhibits mainly bacteriostatic activity and TMP also shows bactericidal activity in urine against susceptible strains. NTX is a more active antibacterial in acidic urine, and TMP is more active in alkaline urine. The cumulative effects of multiple doses or inhibition of bacterial adherence could not be evaluated. (This study has been registered at EudraCT under registration no. 2009-015631-32.).
Department of Urology, Pediatric Urology, and Andrology, Justus Liebig University, Giessen, Germany.
Florian M E
FM
Wagenlehner
Fabian
F
Münch
Adrian
A
Pilatz
Birte
B
Bärmann
Wolfgang
W
Weidner
Christine M
CM
Wagenlehner
Marion
M
Straubinger
Holger
H
Blenk
Wolfgang
W
Pfister
Michael
M
Kresken
Kurt G
KG
Naber
D000900:Anti-Bacterial Agents / Q000493:pharmacokinetics / Q000652:urine*; D001424:Bacterial Infections; D018592:Cross-Over Studies; D004334:Drug Administration Schedule; D004926:Escherichia coli / Q000187:drug effects* / Q000254:growth & development; D064368:Healthy Volunteers; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007711:Klebsiella pneumoniae / Q000187:drug effects* / Q000254:growth & development; D008826:Microbial Sensitivity Tests; D009600:Nitroquinolines / Q000493:pharmacokinetics / Q000652:urine*; D011513:Proteus mirabilis / Q000187:drug effects* / Q000254:growth & development; D057790:Staphylococcus saprophyticus / Q000187:drug effects* / Q000254:growth & development; D014295:Trimethoprim / Q000493:pharmacokinetics / Q000652:urine*; D014552:Urinary Tract Infections
D000900:Anti-Bacterial Agents; D009600:Nitroquinolines; C005308:nitroxoline; D014295:Trimethoprim